- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Role of Guidelines on Molecular Testing in Ovarian Cancer
A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for treatment decisions, prognostic information, and family prevention strategies.
EP: 1.The Role of Guidelines on Molecular Testing in Ovarian Cancer
EP: 2.FRα Biomarker Testing in Patients With Ovarian Cancer
EP: 3.Emerging Molecular Biomarkers in Ovarian Cancer
EP: 4.Comprehensive Molecular Testing in Patients With Ovarian Cancer
EP: 5.The Impact of Tumor Heterogeneity in Ovarian Cancer
EP: 6.Improving Clinician Awareness and Adoption of Molecular Testing
EP: 7.Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer
EP: 8.The Role of Novel Targeted Therapies
EP: 9.The Use of PARP Inhibitors in Ovarian Cancer
EP: 10.Earlier Introduction of Antibody-Drug Conjugates
EP: 11.Approaching Treatment Sequencing In Heavily Pretreated Patients
EP: 12.Single-Agent Vs Combination Regimens
EP: 13.The Potential Impact of Investigational Therapies
EP: 14.Learnings From Key Clinical Trials in Ovarian Cancer
Video content above is prompted by the following:
NCCN Guideline Updates on Molecular Testing
BRCA testing serves 3 critical functions in ovarian cancer management:
- Informs treatment decisions, particularly for PARP inhibitor therapy
- Provides prognostic information (BRCA mutations indicate better response to platinum-based chemotherapy)
- Identifies hereditary risk to enable family testing and risk-reducing surgeries
The comprehensive approach to biomarker testing has shifted from “à la carte” testing to more integrated panel testing performed at diagnosis. This ensures clinicians are prepared with complete molecular information when making treatment decisions.
In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel
June 24th 2025In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.
Read More
